10-10/11 :: October/November 2010
area of importance in cancer research. Further, the data is output in standard basepair format, allowing easier interface with third party tertiary data analysis tools.
http://www.lifetechnologies.com L iquidmetal® Technologies Inc. (OTCBB: LQMT) has named two new members to the Board of
Directors of the Company. Chairman Abdi Mahame- di is welcoming Daniel Young and Ricardo Salas to board seats being vacated by Martin Weinstein and Iraj Azarm.
“Liquidmetal Technologies is grateful for the contri- butions and service of Dr. Weinstein and Mr. Azarm during their tenure as directors. Their insights helped to guide the Company through several complex and important matters,” commented Mr. Mahamedi. “We also look forward to benefiting from the insights and experience that our new directors bring to our Board at this exciting phase in our technology’s com- mercialization.” http://www.liquidmetal.com
umiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation tech-
nology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE: ALGETA), a cancer therapeutics company, have signed a global agreement on incorporation of Lumiphore’s Lumi4® complexes in Algeta’s targeted radiotherapeutics and companion diagnostics. Under the agreement, Algeta has an option to the exclusive rights to incorporate Lumi4®
isophthalamide chelation technology into
future targeted radiopharmaceutical therapeutics for cancer.
“Lumiphore’s goal is to bring the benefits of bifunc- tional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective,” said Dr. Ken Raymond, President and CEO of Lumiphore.
Algeta has proprietary technology relating to the use of the alpha emitter thorium-227 to protein/peptides to target specific cancer cells. Thorium-227 is an isotope that emits high-energy alpha particles. Such isotopes are of considerable interest in the treatment of cancer as they are potent at killing tumor cells but have a highly localized effect. By linking thorium-227 to tumor-targeting molecules such as monoclonal an- tibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals designed to specifically seek and destroy cancers while mini- mizing damage to surrounding healthy tissues.
Lumi4® complexes are a new class of metal lantha-
nide and actinide chelators based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley and modified by Lumiphore. http://www.lumiphore.com htp://www.algeta.com
agForce Nanotechnologies AG (FSE: MF6) announced the expansion of its management
team. The new positions, Director of Intellectual Pro- perty, Director of Business/Corporate Development, Director of Finance & Controlling, and Director of